{"result": "(\"entity\"<|>LIRAGLUTIDA<|>ORGANIZATION<|>Liraglutida is a medication used for weight loss and diabetes management, showing significant effects in clinical studies.)\n##\n(\"entity\"<|>SCALE STUDIES<|>EVENT<|>The SCALE studies are clinical trials that evaluate the effectiveness of liraglutida in weight loss and its impact on various health conditions.)\n##\n(\"entity\"<|>LEADER STUDY<|>EVENT<|>The LEADER study is a long-term clinical trial assessing the cardiovascular safety of liraglutida in patients with diabetes.)\n##\n(\"entity\"<|>SAHS<|>EVENT<|>SAHS refers to the syndrome of sleep apnea-hypopneas, a condition studied in relation to liraglutida's effects on weight loss.)\n##\n(\"entity\"<|>PLACEBO<|>ORGANIZATION<|>Placebo is a control treatment used in clinical trials to compare the effects of liraglutida.)\n##\n(\"relationship\"<|>LIRAGLUTIDA<|>SCALE STUDIES<|>Liraglutida was evaluated in the SCALE studies for its effectiveness in weight loss and other health benefits<|>8)\n##\n(\"relationship\"<|>LIRAGLUTIDA<|>LEADER STUDY<|>Liraglutida's cardiovascular safety was assessed in the LEADER study, indicating its relevance in diabetes management<|>7)\n##\n(\"relationship\"<|>LIRAGLUTIDA<|>SAHS<|>Liraglutida was studied for its effects on patients with SAHS, showing its impact on weight loss in this group<|>6)\n##\n(\"relationship\"<|>LIRAGLUTIDA<|>PLACEBO<|>Liraglutida's effects were compared against placebo in clinical trials to determine its efficacy<|>9)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: |                |                      |             |\n| -6                |                   | -6             | -6,2                 | -5,7        |\n| -7                |                   |                |                      |             |\n| -8                |                   | -8             |                      |             |\n| -9 | -9,2         |                   |                |                      |             |\n| -10               |                   |                |                      |             |\n\n| 27,6 | 75,0 | 27,1 | 63,2 | 13,8 | 49,9 | 21,5 | 50,5 | 18,5 | 46,3 |\n\nSujetos que pierden > 5% peso | Placebo | Lira 3\n\nFigura 1. Resultados de los estudios SCALE (Satiety and Clinical Adiposity - Liraglutide Evidence).\n---\n138      BLOQUE: ALTERACIONES DE LA ENERGÍA\n\nlar para ambas dosis de liragutida, pero la pérdida de peso es mayor, alrededor del 6%, en el grupo de liraglutida 3 mg frente al 2% de placebo27.\n\nLos otros dos estudios SCALE se realizaron para observar las acciones del fármaco en otras situaciones. Así, en el estudio SCALE-mantenimiento28, se confirma que liraglutida 3 mg contribuye a que los pacientes que habían perdido un promedio de un 6% de peso corporal con dieta, conseguían añadir otro 6% de pérdida de peso adicional al ser tratados con el agonista de GLP1. El último estudio a 32 semanas con liraglutida 3 mg se realizó en un grupo de pacientes con síndrome de apneas-hiponeas del sueño (SAHS) que no podían o no querían utilizar el CPAP (SCALE-apneas del sueño)29. En este grupo, la pérdida de peso, similar a los estudios anteriores, supuso además una disminución paralela del número de apneas de estos sujetos29.\n\nEn conjunto, liraglutida presenta una OR de 5,54 (IC 95%, 4,16-7,78) de probabilidades de que los sujetos en tratamiento pierdan ≥ 5% del peso corporal frente a placebo.\n\nEfectos secundarios y seguridad de liraglutida: Los efectos secundarios más comunes fueron las náuseas (15-30% sujetos) y en menor proporción los vómitos (2-10%) como consecuencia de las acciones del fármaco a nivel central, pero, seguramente también debidos al enlentecimiento gástrico. Los efectos fueron menores después de 4 semanas y aún se pueden minimizar si la escalada de dosis es mucho más paulatina. No hay otros efectos secundarios centrales a destacar, por lo que la tolerancia final es buena, siendo la tasa de seguimiento de los estudios muy elevada (un 72% de permanencia, como promedio). La administración del fármaco por vía subcutánea no representó ningún problema de adherencia para los pacientes.\n\nLiraglutida mejora también las cifras de presión arterial y tiene acciones positivas sobre otros marcadores de riesgo cardiovascular. Aunque se ha descrito un incremento de 2-4 latidos/min, este efecto no parece que tenga repercusión clínica alguna y parece reflejar la acción del fármaco a nivel del receptor situado en el nodo seno-auricular. De hecho, liraglutida (hasta una dosis de 1,8 mg) ha demostrado ser seguro desde el punto de vista cardiovascular en las personas con diabetes, tal y como se desprende de los recientes datos obtenidos a largo plazo con el estudio LEADER30.\n\nUno de los principales retos es identificar a los respondedores al tratamiento farmacológico. En un subanálisis del estudio SCALE obesidad y prediabetes, se observó que aquellos que habían perdido ≥ 4% de peso a las 16 semanas del inicio del tratamiento con liraglutida 3 mg, conseguían perder ≥ 5% del peso inicial al cabo de un año. El 77,3% de los participantes tratados con el fármaco se encuentran en esta categoría de respondedores tempranos; y la pérdida promedio de peso a las 56 semanas fue de –10,8% (frente a –3% de los no respondedores tempranos)31.\n\nContraindicaciones y precauciones: Liraglutida 3 mg está contraindicada en pacientes con neoplasia endocrina múltiple (MEN-2), antecedentes de carcinoma medular de tiroides, en enfermedad renal o hepática avanzada, en embarazadas y lactantes, presencia de pancreatitis o colecistitis. Tampoco hay experiencia en adolescentes (< 18 años) o mayores de 75 años. Se debe emplear con precaución en casos con antecedentes de colelitiasis, pancreatitis, gastroparesia o ideación suicida.\n\nDe manera conjunta y atendiendo a los resultados principales de los ensayos clínicos de cada fármaco de los aquí comentados, podemos advertir que la\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}